Clinical Trials

Petosemtamab
(MCLA-158)
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Petosemtamab (MCLA-158) is being developed for the potential treatment of head and neck squamous cell carcinoma (HNSCC). Our phase 1/2 clinical trial of petosemtamab is ongoing in the dose expansion phase of the open-label, multicenter trial. Enrollment of patients with HNSCC continues, evaluating petosemtamab monotherapy in 2L+ HNSCC, as well as petosemtamab in combination with pembrolizumab in first line HNSCC. The evaluation of petosemtamab in combination with standard chemotherapy in 2L colorectal cancer patients is planned to start in 2024.

More information is available at the clinicaltrials.gov website.

Zenocutuzumab
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy trial)

Zeno (zenocutuzumab, or MCLA-128) is being developed for the potential treatment of NRG1 fusion (NRG1+) lung, pancreas and other cancers. Our eNRGy trial, a phase 1/2 clinical trial is an ongoing open-label, multicenter trial enrolling patients with NRG1+ solid tumors. The FDA has accepted for priority review a Biologics License Application for Zeno for the treatment of NRG1+ non-small cell lung and pancreatic cancer.

Further details about the eNRGy clinical trial for Zeno, including current trial sites, can be found at Merus™ trial website at http://www.nrg1.com or by calling 1-833-NRG-1234.

More information is available at the clinicaltrials.gov website.

Early Access Program
Patients with NRG1+ cancer that are otherwise unable to participate in an applicable clinical trial may be eligible to participate in the Early Access Program for Zeno (MCLA-128). Further details about the Zeno Early Access Program can be found at Merus™ trial website www.nrg1.com or by calling 1-833-NRG-1234. Details on Merus™ Early Access Policy are available here. Information is also available at the clinicaltrials.gov website: Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
MCLA-129
A Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

MCLA-129 is currently being developed for the potential treatment of advanced non-small cell lung cancer (NSCLC) and other solid tumors. Our phase 1/2 trial is ongoing in the dose expansion phase of the open-label, multicenter trial. Enrollment of patients in dose expansion cohorts continues, evaluating MCLA-129 monotherapy in MET ex14 NSCLC. The evaluation of MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC is planned to start in 2024. 

More information is available at the clinicaltrials.gov website.

MCLA-145
A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

MCLA-145 is currently being developed for the potential treatment of solid tumors in a phase 1 open-label, multicenter trial. The trial is in the dose expansion phase evaluating the combination of MCLA-145 with pembrolizumab.

More information is available at the clinicaltrials.gov website.

 

Unless otherwise noted, we are providing this information as of May 8, 2024. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Merus’ most recent Quarterly Report on Form 10-Q and in Merus’ other periodic reports on Form 10-Q and Form 8-K filed with the SEC, and actual results may vary materially. Merus provides this information as of the date above and does not undertake any obligation to update any forward-looking statements contained on these tables as a result of new information, future events or otherwise.

All Company therapeutic candidates described or mentioned herein are investigational and have not yet been approved for marketing by any regulatory authority.